Analysts See $-0.41 EPS for Advaxis, Inc. (ADXS)

May 20, 2018 - By Adrian Mccoy

Advaxis, Inc. (NASDAQ:ADXS) LogoInvestors sentiment decreased to 1.12 in Q4 2017. Its down 0.11, from 1.23 in 2017Q3. It dropped, as 17 investors sold Advaxis, Inc. shares while 17 reduced holdings. 16 funds opened positions while 22 raised stakes. 15.17 million shares or 10.45% less from 16.94 million shares in 2017Q3 were reported.
Victory Capital Management has 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 5,316 shares. Deutsche Bancorporation Ag invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Alliancebernstein Ltd Partnership holds 75,300 shares. Moreover, Cutler Cap Management Limited Liability Corporation has 0.09% invested in Advaxis, Inc. (NASDAQ:ADXS). Natl Bank Of Mellon invested 0% in Advaxis, Inc. (NASDAQ:ADXS). 129,800 were reported by Franklin Street Advisors Incorporated Nc. Northern Tru owns 440,175 shares or 0% of their US portfolio. Parallax Volatility Advisers Lp invested in 0% or 5,502 shares. Jane Street Group Llc has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). 542,230 are owned by Fmr. Parametric Portfolio Assoc Limited Liability Corporation reported 0% in Advaxis, Inc. (NASDAQ:ADXS). Price T Rowe Md holds 57,100 shares or 0% of its portfolio. Wolverine Asset Lc, a Illinois-based fund reported 2,389 shares. California State Teachers Retirement Sys reported 58,649 shares. Dimensional Fund Advisors Limited Partnership invested in 54,273 shares or 0% of the stock.

Since December 29, 2017, it had 0 buys, and 3 sales for $20,259 activity. On Thursday, March 29 PETIT ROBERT sold $3,553 worth of Advaxis, Inc. (NASDAQ:ADXS) or 2,193 shares. The insider Bonstein Sara sold 5,224 shares worth $16,612.

Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $-0.41 EPS on June, 5.They anticipate $0.10 EPS change or 19.61 % from last quarter’s $-0.51 EPS. After having $-0.49 EPS previously, Advaxis, Inc.’s analysts see -16.33 % EPS growth. The stock increased 5.65% or $0.1 during the last trading session, reaching $1.87. About 452,898 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has declined 77.70% since May 20, 2017 and is downtrending. It has underperformed by 89.25% the S&P500.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Among 2 analysts covering Advaxis (NASDAQ:ADXS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis had 3 analyst reports since December 27, 2017 according to SRatingsIntel. H.C. Wainwright maintained Advaxis, Inc. (NASDAQ:ADXS) on Wednesday, December 27 with “Buy” rating. The firm has “Overweight” rating given on Tuesday, March 13 by Cantor Fitzgerald. H.C. Wainwright maintained Advaxis, Inc. (NASDAQ:ADXS) on Wednesday, March 14 with “Buy” rating.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $97.83 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

More news for Advaxis, Inc. (NASDAQ:ADXS) were recently published by:, which released: “Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith …” on May 14, 2018.‘s article titled: “Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent” and published on May 11, 2018 is yet another important article.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.